GIVAX

Givax is a Swiss biotechnology company focused on the development of a human vaccine against Giardia lamblia, a prevalent intestinal parasite that causes giardiasis. The company's lead program utilizes a recombinant protein approach to target the parasite's surface proteins, aiming to provide long-term immunity and prevent infection in both children and adults. Founded as a spin-off from the University of Geneva, Givax leverages specialized expertise in parasitology and immunology to address a significant global health burden that currently lacks an approved human vaccine. The company is currently advancing its candidate through pre-clinical validation and optimization of its proprietary vaccine formulation.